Waters Corporation reports recurring developments across life sciences and diagnostics, including analytical instruments, informatics, service, and high-volume testing workflows. News for WAT commonly covers operating results and guidance, the Analytical Sciences Division, and the Biosciences and Diagnostic Solutions businesses added through the completed BD transaction.
Company updates also include product launches for liquid chromatography, UPLC and UHPLC workflows, MALS detection, rheometry, LC columns, and TA Instruments technologies. Diagnostic news includes FDA-related developments for the Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, along with commercial, conference, and shareholder-related updates.
Waters Corporation (NYSE:WAT) will present at the J.P. Morgan Healthcare Conference on January 9, 2023, at 4:30 PM PST. Udit Batra, CEO, will discuss key topics with investors. The event can be accessed via a live webcast on Waters' investor relations website, with a replay available for 30 days. Waters has been a leader in analytical instruments and software for over 60 years, specializing in chromatography and mass spectrometry, with a presence in over 100 countries and more than 7,800 employees.
Summary not available.
Waters Corporation (NYSE:WAT) has appointed Dan Brennan and Mark Vergnano to its Board of Directors, effective November 23, 2022. Brennan, currently CFO at Boston Scientific, and Vergnano, former CEO of The Chemours Company, bring extensive experience crucial for Waters' growth strategy. Their addition follows a robust board refreshment process, making the board nine members strong, with eight independent. Chairman Dr. Flemming Ornskov highlights their potential to enhance operational and financial expertise as Waters implements its growth initiatives.
Waters Corporation has launched a new PFAS quantitation workflow that simplifies the detection of Per- and Polyfluoroalkyl Substances (PFAS) in various environmental samples. This end-to-end solution can measure parts-per-quadrillion (ppq) levels, exceeding regulatory limits, and includes automated data processing through the waters_connect software. This innovation aims to streamline laboratory operations while reducing manual errors in PFAS measurement, addressing increasing regulatory requirements.
Waters Corporation (NYSE:WAT) will participate in the Evercore ISI HealthconX Conference on November 29th, 2022. Udit Batra, Ph.D., the President and CEO, will engage in a virtual fireside chat from 1:00-1:45 PM EST. Investors can access the live webcast on the company's investor relations website and a replay will be available for 30 days.
Waters is a global leader in analytical instruments and software, with over 7,800 employees and operations in over 35 countries, specializing in chromatography and mass spectrometry.
Summary not available.
Waters Corporation (NYSE: WAT) reported Q3 2022 sales of $709 million, reflecting a 7% increase as reported and 15% in constant currency. Key highlights include a 21% surge in instrument sales and strong revenue growth across all major geographies, particularly a 23% increase in China. Recurring revenues rose 10% in constant currency. GAAP EPS remained stable at $2.60, while non-GAAP EPS slightly declined to $2.64. Waters raised its full-year 2022 sales growth guidance to 11.5%-12%, despite a 6% unfavorable currency impact. For Q4, it projects sales growth of 6%-8% and non-GAAP EPS of $3.66-$3.76, factoring in currency headwinds.
Waters Corporation has launched the Extraction+ Connected Device, which automates solid phase extraction (SPE) methods, significantly reducing sample preparation time by up to four hours per sample set. This innovation, compatible with the Andrew+ Pipetting Robot and controlled through OneLab Software, minimizes user variability and enhances assay reproducibility. The device is now available globally, marking a step forward in laboratory efficiency for biological, food, forensic, and environmental applications.
Waters Corporation (NYSE:WAT) announced a multi-year investment of up to €6 million, supported by IDA Ireland, to enhance its research and development operations in Wexford, Ireland. This expansion aims to create new scientific jobs and focus on clinical diagnostic solutions. Waters commemorates its 25th anniversary in Ireland, reinforcing its commitment to advancing mass spectrometry technologies for early disease detection. The Wexford facility is vital for manufacturing in-vitro diagnostic systems and aims to improve diagnostic accuracy for various medical conditions.
Waters Corporation (NYSE:WAT) will announce its Q3 2022 financial results in a conference call on November 1, 2022, at 8:00 a.m. ET. The presentation will be accessible through a live webcast on Waters’ investor relations website. A replay option will be available until November 15, 2022, at midnight ET. Waters Corporation has over 60 years of experience in analytical instruments and software, serving various sectors, including life sciences and materials, with a workforce of more than 7,800 employees.